In 1974, in Nature, one of us has proposed a radically new idea that led to the development of anticytokine therapy which is now used around the world for the treatment of autoimmune diseases. We were the first to use...In 1974, in Nature, one of us has proposed a radically new idea that led to the development of anticytokine therapy which is now used around the world for the treatment of autoimmune diseases. We were the first to use antibodies to IFN-γ and were some of the first to suggest using antagonists of TNF-α in the treatment of autoimmune and inflammatory diseases as well. Our method suppresses one of the main pathogenetic mechanisms of these diseases. Antibodies to IFN-γ and TNF-α exhibit dramatic effects on clinical manifestations of rheumatoid arthritis (RA). However, in our trial ultrasound assessment of the synovial membrane thickness in RA patients showed that only anti-IFN-γ exerted pronounced anti-inflammatory effect. Some patients who underwent treatment with antibodies to TNF-α developed a number of complications. Anticytokine therapy (mono- and poly-) alone or in combination with other drugs can possibly be used not only in the treatment of autoimmune diseases, but also in other pathologies with cytokine synthesis disturbances (a number of neurological, psychiatric, endocrine, and other diseases).展开更多
Primary cancers can be prevented by immunizations. We suggest immunizing healthy people, especially the ones with genetic predisposition to cancer, with a standard oncoantigen. In patients suffering from cancer, immun...Primary cancers can be prevented by immunizations. We suggest immunizing healthy people, especially the ones with genetic predisposition to cancer, with a standard oncoantigen. In patients suffering from cancer, immunotherapy can be effective only if it is administered during complete remission. Immune competent cells, like T-lymphocytes and bone marrow, are the most important components for cancer prevention and treatment. Because of the dramatic increase in the incidence of cancer, it is important to offer all adults with absolutely healthy immune system an opportunity to donate their own T-lymphocytes and bone marrow cells and preserve them at -196。C. These cells can later be used by the same people in auto-system if they develop cancer. Patients who had their cancerous tumors surgically removed can also have their own T-lymphocytes and bone marrow cells collected during remission and then used in auto-system in case of cancer reoccurrence. It is also possible to impact on cancer development during the process of cancerogenesis by administering large amounts of normal DNA and possibly different types of RNA (displacement) together with nucleases (directly into the tumor or blood). In addition, blockers of cytokines that suppress immune system should be administered as well. It is intriguing to think that injection of large amounts of normal DNA and possibly different types of RNA together with nucleases to patients with chronic and hereditary diseases (diabetes Type II, schizophrenia, and other similar diseases) can lead to therapeutic effect.展开更多
In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it w...In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.展开更多
文摘In 1974, in Nature, one of us has proposed a radically new idea that led to the development of anticytokine therapy which is now used around the world for the treatment of autoimmune diseases. We were the first to use antibodies to IFN-γ and were some of the first to suggest using antagonists of TNF-α in the treatment of autoimmune and inflammatory diseases as well. Our method suppresses one of the main pathogenetic mechanisms of these diseases. Antibodies to IFN-γ and TNF-α exhibit dramatic effects on clinical manifestations of rheumatoid arthritis (RA). However, in our trial ultrasound assessment of the synovial membrane thickness in RA patients showed that only anti-IFN-γ exerted pronounced anti-inflammatory effect. Some patients who underwent treatment with antibodies to TNF-α developed a number of complications. Anticytokine therapy (mono- and poly-) alone or in combination with other drugs can possibly be used not only in the treatment of autoimmune diseases, but also in other pathologies with cytokine synthesis disturbances (a number of neurological, psychiatric, endocrine, and other diseases).
文摘Primary cancers can be prevented by immunizations. We suggest immunizing healthy people, especially the ones with genetic predisposition to cancer, with a standard oncoantigen. In patients suffering from cancer, immunotherapy can be effective only if it is administered during complete remission. Immune competent cells, like T-lymphocytes and bone marrow, are the most important components for cancer prevention and treatment. Because of the dramatic increase in the incidence of cancer, it is important to offer all adults with absolutely healthy immune system an opportunity to donate their own T-lymphocytes and bone marrow cells and preserve them at -196。C. These cells can later be used by the same people in auto-system if they develop cancer. Patients who had their cancerous tumors surgically removed can also have their own T-lymphocytes and bone marrow cells collected during remission and then used in auto-system in case of cancer reoccurrence. It is also possible to impact on cancer development during the process of cancerogenesis by administering large amounts of normal DNA and possibly different types of RNA (displacement) together with nucleases (directly into the tumor or blood). In addition, blockers of cytokines that suppress immune system should be administered as well. It is intriguing to think that injection of large amounts of normal DNA and possibly different types of RNA together with nucleases to patients with chronic and hereditary diseases (diabetes Type II, schizophrenia, and other similar diseases) can lead to therapeutic effect.
文摘In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.
